New imaging confirms ocrelizumab’s impact on lesion activity in multiple sclerosis

Healio quotes Michael Dwyer in an article about a drug, Ocrelizumab, that significantly reduced the number and volume of cortical lesions associated with multiple sclerosis. “Gray matter is increasingly recognized as a key component in MS despite the focus on white matter, and we know that cortical lesions commonly occur very early and are very prevalent,” said Dwyer. “They associate very strongly with disability and cognition.”